Non-replicating chimpanzee adenovirus vector. Phase 1/2 trial with 510 subjects aged 18-55 at four centers in the United Kingdom. The trial will test safety and immunogenicity of one or two doses of the vaccine, and is expected to be completed in May 2021.
, , , et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. May 13, 2020. DOI: 10.1101/2020.05.13.093195
Morven Wilkie, Iman Satti, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults. Vaccine. Volume 38, Issue 4, 22 January 2020, Pages 779-789. DOI: 10.1016/j.vaccine.2019.10.102.
Vaccine. 2020 Jan 22;38(4):779-789. DOI: 10.1016/j.vaccine.2019.10.102.